PL2361924T3 - Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego - Google Patents

Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego

Info

Publication number: PL2361924T3
Authority: PL; Poland
Prior art keywords: mixtures; preparation; hydrobromic acid; glatiramer acetate; trifluoroacetyl glatiramer
Prior art date: 2004-09-09

Application number

PL10194363T

Other languages

English (en)

Inventor

Ben-Zion Dolitzky

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-09

Filing date

2005-09-09

Publication date

2014-08-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36037047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2361924(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-09-09 Application filed by Teva Pharma filed Critical Teva Pharma

2014-08-29 Publication of PL2361924T3 publication Critical patent/PL2361924T3/pl

Links

239000000203 mixture Substances 0.000 title abstract 3
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 title 1
108010072051 Glatiramer Acetate Proteins 0.000 title 1
229960003776 glatiramer acetate Drugs 0.000 title 1
-1 trifluoroacetyl glatiramer acetate Chemical compound 0.000 title 1
229920001184 polypeptide Polymers 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 3
108090000765 processed proteins & peptides Proteins 0.000 abstract 3
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 abstract 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
239000004472 Lysine Substances 0.000 abstract 1
235000004279 alanine Nutrition 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
235000013922 glutamic acid Nutrition 0.000 abstract 1
239000004220 glutamic acid Substances 0.000 abstract 1
239000012535 impurity Substances 0.000 abstract 1
235000018977 lysine Nutrition 0.000 abstract 1
229910021645 metal ion Inorganic materials 0.000 abstract 1
235000002374 tyrosine Nutrition 0.000 abstract 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
150000003668 tyrosines Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Zoology (AREA)
Toxicology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Rheumatology (AREA)
Rehabilitation Therapy (AREA)
Transplantation (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

PL10194363T 2004-09-09 2005-09-09 Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego PL2361924T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US60884304P	2004-09-09	2004-09-09
EP10194363.7A EP2361924B1 (en)	2004-09-09	2005-09-09	Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
EP10150124A EP2177528B1 (en)	2004-09-09	2005-09-09	Process for the preparation of mixtures of trifluoroacetyl glatiramer acetate using purified hydrobromic acid
EP05791236A EP1799703B1 (en)	2004-09-09	2005-09-09	Process for preparation of mixtures of polypeptides using purified hydrobromic acid

Publications (1)

Publication Number	Publication Date
PL2361924T3 true PL2361924T3 (pl)	2014-08-29

Family

ID=36037047

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
PL05791236T PL1799703T3 (pl)	2004-09-09	2005-09-09	Sposób wytwarzania mieszaniny polipeptydów stosując oczyszczony kwas bromowodorowy
PL10150124T PL2177528T3 (pl)	2004-09-09	2005-09-09	Sposób wytwarzania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego
PL10194363T PL2361924T3 (pl)	2004-09-09	2005-09-09	Proces przygotowania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL05791236T PL1799703T3 (pl)	2004-09-09	2005-09-09	Sposób wytwarzania mieszaniny polipeptydów stosując oczyszczony kwas bromowodorowy
PL10150124T PL2177528T3 (pl)	2004-09-09	2005-09-09	Sposób wytwarzania mieszanin octanu trifluoroacetyloglatirameru z zastosowaniem oczyszczonego kwasu bromowodorowego

Country Status (27)

Country	Link
US (2)	US7495072B2 (pl)
EP (3)	EP2361924B1 (pl)
JP (1)	JP5149008B2 (pl)
KR (1)	KR101317131B1 (pl)
CN (1)	CN101166754B (pl)
AT (2)	ATE536363T1 (pl)
AU (1)	AU2005282249B2 (pl)
BR (1)	BRPI0515033B1 (pl)
CA (1)	CA2579656C (pl)
CY (1)	CY1110280T1 (pl)
DE (1)	DE602005018800D1 (pl)
DK (3)	DK1799703T3 (pl)
ES (3)	ES2451006T3 (pl)
HR (3)	HRP20100164T1 (pl)
IL (2)	IL181596A (pl)
IS (1)	IS8622A (pl)
MX (1)	MX2007002760A (pl)
NO (1)	NO20071632L (pl)
NZ (1)	NZ554018A (pl)
PL (3)	PL1799703T3 (pl)
PT (3)	PT2361924E (pl)
RS (3)	RS53248B (pl)
RU (1)	RU2388764C2 (pl)
SI (3)	SI2177528T1 (pl)
UA (1)	UA91029C2 (pl)
WO (1)	WO2006029393A2 (pl)
ZA (1)	ZA200702591B (pl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
EP1098902A4 (en)	1998-07-23	2002-07-24	Yeda Res & Dev	TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
US6800287B2 (en) *	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2002076503A1 (en) *	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
EP1459065B1 (en) *	2001-12-04	2010-07-28	Teva Pharmaceutical Industries, Ltd.	Processes for the measurement of the potency of glatiramer acetate
EP1778286A4 (en) *	2004-03-03	2009-04-08	Teva Pharma	COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE
DK1799703T3 (da) *	2004-09-09	2010-04-19	Teva Pharma	Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
HRP20160455T1 (hr) *	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
DE602005016292D1 (de) *	2004-10-29	2009-10-08	Sandoz Ag	Verfahren zur herstellung von glatiramer
US8324641B2 (en) *	2007-06-29	2012-12-04	Ledengin, Inc.	Matrix material including an embedded dispersion of beads for a light-emitting device
US20060172942A1 (en) *	2005-02-02	2006-08-03	Teva Pharmaceutical Industries, Ltd.	Process for producing polypeptide mixtures using hydrogenolysis
RS52867B (sr) *	2005-02-17	2013-12-31	Teva Pharmaceutical Industries Ltd.	Kombinovana terapija glatiramer acetatom i razagilinom za lečenje multiple skleroze
US20060240463A1 (en) *	2005-04-25	2006-10-26	Rappaport Family Institute For Research In The Medical Sciences	Markers associated with the therapeutic efficacy of glatiramer acetate
US20090035816A1 (en) *	2007-08-02	2009-02-05	Scinopharm Taiwan Ltd.	Process for the preparation of a polypeptide
WO2009070298A1 (en) *	2007-11-28	2009-06-04	Teva Pharmaceutical Industries, Ltd.	Method of delaying the onset of clinically definite multiple sclerosis
ES2449865T5 (es) *	2008-04-16	2022-11-18	Momenta Pharmaceuticals Inc	Análisis de composiciones de copolímeros de aminoácidos
PL2307448T3 (pl) *	2008-08-07	2015-10-30	Sigma Aldrich Co Llc	Wytwarzanie polilizyny i poliornityny o małym ciężarze cząsteczkowym z wysoką wydajnością
KR20110059606A (ko) *	2008-08-07	2011-06-02	시노팜 타이완 리미티드	글라티라머 아세테이트의 합성
RU2011144566A (ru)	2009-04-03	2013-05-10	Момента Фармасьютикалз, Инк.	Контроль сополимерных композиций
RS55607B1 (sr)	2009-08-20	2017-06-30	Yeda Research & Development Company Ltd	Niskofrekventna terapija glatiramer acetatom
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) *	2010-03-16	2014-06-24	Teva Pharmaceutical Industries, Ltd.	Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
MX2012012489A (es) *	2010-04-27	2012-12-17	Reddys Lab Ltd Dr	Preparacion de polipeptidos y sales de los mismos.
EA025780B1 (ru)	2010-10-11	2017-01-30	Тева Фармасьютикал Индастриз Лтд.	Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
US8788046B2 (en)	2010-11-11	2014-07-22	Spr Therapeutics, Llc	Systems and methods for the treatment of pain through neural fiber stimulation
ES2654291T3 (es)	2011-02-14	2018-02-13	Usv Private Limited	Copolímero-1, proceso para la preparación y sus métodos de análisis
JP5701103B2 (ja) *	2011-03-02	2015-04-15	昭和シェル石油株式会社	潤滑油のための消泡剤組成物及びそれを用いた消泡方法
ES2601892T3 (es)	2011-04-21	2017-02-16	Mapi Pharma Limited	Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2013009885A2 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Evaluation of copolymer diethylamide
WO2013009864A1 (en)	2011-07-11	2013-01-17	Momenta Pharmaceuticals, Inc.	Structure assessment of heterogeneous polypeptide mixtures
US8575198B1 (en)	2011-09-07	2013-11-05	Momenta Pharmaceuticals, Inc.	In-process control for the manufacture of glatiramer acetate
MX2014004309A (es)	2011-10-10	2015-07-06	Teva Pharma	Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
CN102717992A (zh) *	2012-05-30	2012-10-10	苏州市旭洋工业搪瓷厂	一种搪玻璃溴素贮罐
CN102718963B (zh) *	2012-06-19	2014-10-15	深圳翰宇药业股份有限公司	聚合物多肽的制备方法
WO2014058976A2 (en)	2012-10-10	2014-04-17	Teva Pharmaceutical Industries Ltd.	Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es)	2013-10-21	2015-05-29	Teva Pharma	Marcadores genéticos que predicen la respuesta al acetato de glatiramer
WO2015066515A1 (en)	2013-11-01	2015-05-07	Receptos, Inc.	Selective sphingosine 1 phosphate receptor modulators and combination therapy therewith
CN104844697B (zh) *	2014-09-26	2018-10-23	深圳翰宇药业股份有限公司	醋酸格拉替雷的制备方法
US9155775B1 (en)	2015-01-28	2015-10-13	Teva Pharmaceutical Industries, Ltd.	Process for manufacturing glatiramer acetate product
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en)	2016-08-31	2024-09-05	Mapi Pharma Ltd	Depot systems comprising glatiramer acetate
IL316573A (en)	2017-03-26	2024-12-01	Mapi Pharma Ltd	Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US20190202984A1 (en) *	2018-01-03	2019-07-04	Kinbio Ltd.	Process of preparing glatiramer acetate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3846550A (en) *	1971-01-21	1974-11-05	H Akrongold	Cosmetic skin powder containing urea
IL36670A (en) *	1971-04-21	1974-09-10	Sela M	Therapeutic basic copolymers of amino acids
JPS54119499A (en) *	1978-03-09	1979-09-17	Shionogi & Co Ltd	Triazolobenzodiazepin derivative
JPS6053535A (ja) *	1983-09-02	1985-03-27	Nitto Boseki Co Ltd	規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru)	1984-04-28	1985-09-30	Таджикский государственный университет им.В.И.Ленина	Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AU596986B2 (en)	1985-06-18	1990-05-24	Emory University	Biologically-active copolymers
DD257174A3 (de)	1985-12-20	1988-06-08	Ve Forschungszentrum Biotechno	Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru)	1986-05-30	1995-11-20	Институт Высокомолекулярных Соединений Ан Ссср	Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
SU1690368A1 (ru)	1989-07-20	1995-08-20	Институт Высокомолекулярных Соединений Ан Ссср	Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de)	1989-09-14	1991-03-28	Roehm Gmbh	Verfahren zur herstellung eines komplexierten arzneimittels
USH1312H (en) *	1992-05-28	1994-05-03	Cytogen Corporation	Method for the preparation of gyk-dtpa
IL113812A (en) *	1994-05-24	2000-06-29	Yeda Res & Dev	Copolymer-1 pharmaceutical compositions containing it and its use
RU2198900C2 (ru) *	1994-05-24	2003-02-20	Еда Рисерч энд Дивелопмент Ко., Лтд.	Усовершенствованный сополимер-1 и способ его получения
US5858964A (en) *	1995-04-14	1999-01-12	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
FR2750423B1 (fr)	1996-06-28	1998-08-14	Rhone Poulenc Chimie	Procede d'hydrogenation asymetrique d'un compose cetonique
US6214791B1 (en) *	1997-01-10	2001-04-10	Yeda Research And Development Co. Ltd.	Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
WO1999016747A1 (en)	1997-09-30	1999-04-08	Daiichi Pharmaceutical Co., Ltd.	Sulfonyl derivatives
US5872122A (en) *	1997-10-16	1999-02-16	Monsanto Company	Pyrimidinylamidino β-amino acid derivatives useful as inhibitors of platelet aggregation
US5965047A (en)	1997-10-24	1999-10-12	Steag Ast	Rapid thermal processing (RTP) system with rotating substrate
GB9724627D0 (en)	1997-11-20	1998-01-21	Genencor Int Bv	Gram positive microorganism formate pathway
EP1098902A4 (en)	1998-07-23	2002-07-24	Yeda Res & Dev	TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
ES2527760T3 (es) *	1998-07-23	2015-01-29	Yeda Research And Development Co., Ltd.	Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US6800287B2 (en) *	1998-09-25	2004-10-05	Yeda Research And Development Co., Ltd.	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6514938B1 (en)	1998-09-25	2003-02-04	Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science	Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
AU775073C (en)	1998-11-12	2007-05-03	Yeda Research And Development Co. Ltd.	Pharmaceutical compositions comprising synthetic peptide copolymers and methods for preventing and treating GVHD and HVGD
US6114649A (en)	1999-07-13	2000-09-05	Duran Technologies Inc.	Anode electrode for plasmatron structure
EP1250450A2 (en)	1999-09-03	2002-10-23	University of Iowa Research Foundation Inc.	Quorum sensing signaling in bacteria
DE19944003C1 (de)	1999-09-14	2001-03-22	Baumeister & Ostler Gmbh Co	Faltbare Trenneinrichtung
HK1054507B (zh) *	2000-01-20	2008-10-31	耶达研究及发展有限公司	共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
US7022663B2 (en) *	2000-02-18	2006-04-04	Yeda Research And Development Co., Ltd.	Oral, nasal and pulmonary dosage formulations of copolymer 1
MXPA02008023A (es)	2000-02-18	2005-06-30	Yeda Res & Dev	Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
US20020077278A1 (en)	2000-06-05	2002-06-20	Yong V. Wee	Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
DE60116467T2 (de)	2000-06-07	2006-11-02	Yeda Research And Development Co., Ltd.	Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
WO2002076503A1 (en)	2000-06-20	2002-10-03	Mayo Foundation For Medical Education And Research	Treatment of central nervous system diseases by antibodies against glatiramer acetate
JP3698984B2 (ja)	2000-11-10	2005-09-21	ヤマウチ株式会社	シュープレス用ベルト
CA2430037A1 (en) *	2000-11-20	2002-05-30	Michael S. South	Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
JP3661935B2 (ja)	2001-06-20	2005-06-22	ソニー株式会社	情報処理装置および方法、記録媒体、並びにプログラム
EP1459065B1 (en) *	2001-12-04	2010-07-28	Teva Pharmaceutical Industries, Ltd.	Processes for the measurement of the potency of glatiramer acetate
WO2004036172A2 (en)	2002-05-09	2004-04-29	Dennis Farwell	Bioweapon-detecting fibrous-network products and methods for making same
WO2004043995A2 (en) *	2002-11-13	2004-05-27	Apotex Pharmachem Inc.	Process for the preparation of glatiramer acetate by polymerisation of n-carboxy anhydrides of l-alanine, l-tyrosine, benzyl l-glutamate and benzyloxycarbonyl l-lysine
CA2411786C (en) *	2002-11-13	2009-01-27	Brantford Chemicals Inc.	A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids
DE10353960B4 (de)	2003-10-16	2006-03-23	Vertilas Gmbh	Oberflächenemittierender Halbleiterlaser mit strukturiertem Wellenleiter
DK1799703T3 (da)	2004-09-09	2010-04-19	Teva Pharma	Fremgangsmåde til fremstilling af blandinger af polypeptider ved hjælp af oprenset hydrogenbromid
HRP20160455T1 (hr) *	2004-09-09	2016-07-15	Yeda Research And Development Co., Ltd.	Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
US20060172942A1 (en) *	2005-02-02	2006-08-03	Teva Pharmaceutical Industries, Ltd.	Process for producing polypeptide mixtures using hydrogenolysis
US20060240463A1 (en) *	2005-04-25	2006-10-26	Rappaport Family Institute For Research In The Medical Sciences	Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007072865A1 (ja)	2005-12-22	2007-06-28	Pioneer Corporation	施設情報配信装置、通信端末、施設情報配信方法、情報出力方法、プログラム、および記録媒体

2005
- 2005-09-09 DK DK05791236.2T patent/DK1799703T3/da active
- 2005-09-09 MX MX2007002760A patent/MX2007002760A/es active IP Right Grant
- 2005-09-09 US US11/223,072 patent/US7495072B2/en not_active Expired - Lifetime
- 2005-09-09 ZA ZA200702591A patent/ZA200702591B/xx unknown
- 2005-09-09 DK DK10194363.7T patent/DK2361924T3/en active
- 2005-09-09 SI SI200531482T patent/SI2177528T1/sl unknown
- 2005-09-09 CN CN200580033851.5A patent/CN101166754B/zh not_active Expired - Lifetime
- 2005-09-09 DK DK10150124.5T patent/DK2177528T3/da active
- 2005-09-09 UA UAA200703838A patent/UA91029C2/uk unknown
- 2005-09-09 AT AT10150124T patent/ATE536363T1/de active
- 2005-09-09 ES ES10194363.7T patent/ES2451006T3/es not_active Expired - Lifetime
- 2005-09-09 AT AT05791236T patent/ATE454396T1/de active
- 2005-09-09 PT PT101943637T patent/PT2361924E/pt unknown
- 2005-09-09 DE DE602005018800T patent/DE602005018800D1/de not_active Expired - Lifetime
- 2005-09-09 BR BRPI0515033-7A patent/BRPI0515033B1/pt not_active IP Right Cessation
- 2005-09-09 EP EP10194363.7A patent/EP2361924B1/en not_active Revoked
- 2005-09-09 NZ NZ554018A patent/NZ554018A/en not_active IP Right Cessation
- 2005-09-09 PL PL05791236T patent/PL1799703T3/pl unknown
- 2005-09-09 PT PT10150124T patent/PT2177528E/pt unknown
- 2005-09-09 EP EP10150124A patent/EP2177528B1/en not_active Revoked
- 2005-09-09 ES ES05791236T patent/ES2338138T3/es not_active Expired - Lifetime
- 2005-09-09 RS RS20140097A patent/RS53248B/sr unknown
- 2005-09-09 ES ES10150124T patent/ES2382298T3/es not_active Expired - Lifetime
- 2005-09-09 AU AU2005282249A patent/AU2005282249B2/en not_active Expired
- 2005-09-09 PL PL10150124T patent/PL2177528T3/pl unknown
- 2005-09-09 KR KR1020077007738A patent/KR101317131B1/ko not_active Expired - Lifetime
- 2005-09-09 RU RU2007112956/04A patent/RU2388764C2/ru active
- 2005-09-09 HR HR20100164T patent/HRP20100164T1/hr unknown
- 2005-09-09 PT PT05791236T patent/PT1799703E/pt unknown
- 2005-09-09 PL PL10194363T patent/PL2361924T3/pl unknown
- 2005-09-09 SI SI200531830T patent/SI2361924T1/sl unknown
- 2005-09-09 RS RS20120091A patent/RS52265B/sr unknown
- 2005-09-09 EP EP05791236A patent/EP1799703B1/en not_active Revoked
- 2005-09-09 WO PCT/US2005/032395 patent/WO2006029393A2/en not_active Ceased
- 2005-09-09 SI SI200530934T patent/SI1799703T1/sl unknown
- 2005-09-09 JP JP2007531423A patent/JP5149008B2/ja not_active Expired - Fee Related
- 2005-09-09 CA CA2579656A patent/CA2579656C/en not_active Expired - Lifetime
- 2005-09-09 RS RSP-2010/0114A patent/RS51257B/sr unknown
2006
- 2006-09-27 US US11/529,668 patent/US20070021324A1/en not_active Abandoned
2007
- 2007-02-27 IL IL181596A patent/IL181596A/en active IP Right Grant
- 2007-03-16 IS IS8622A patent/IS8622A/is unknown
- 2007-03-28 NO NO20071632A patent/NO20071632L/no not_active Application Discontinuation
2010
- 2010-03-31 CY CY20101100308T patent/CY1110280T1/el unknown
2012
- 2012-03-02 HR HRP20120209TT patent/HRP20120209T1/hr unknown
2014
- 2014-03-10 HR HRP20140216TT patent/HRP20140216T1/hr unknown
2015
- 2015-09-17 IL IL241702A patent/IL241702A0/en unknown

Also Published As

Publication number	Publication date
WO2006029393A8 (en)	2007-04-19
DK1799703T3 (da)	2010-04-19
CA2579656A1 (en)	2006-03-16
IL241702A0 (en)	2015-11-30
CY1110280T1 (el)	2015-01-14
WO2006029393A2 (en)	2006-03-16
EP2361924A1 (en)	2011-08-31
SI2177528T1 (sl)	2012-04-30
EP2177528A1 (en)	2010-04-21
NO20071632L (no)	2007-06-05
HK1100780A1 (en)	2007-09-28
ZA200702591B (en)	2009-03-25
NZ554018A (en)	2009-06-26
ATE454396T1 (de)	2010-01-15
BRPI0515033B1 (pt)	2021-05-25
BRPI0515033A (pt)	2008-07-01
JP2008512494A (ja)	2008-04-24
HRP20140216T1 (hr)	2014-06-06
US20060052586A1 (en)	2006-03-09
HRP20100164T1 (hr)	2010-07-31
EP2361924B1 (en)	2013-12-11
CA2579656C (en)	2014-11-04
ES2382298T3 (es)	2012-06-07
DK2361924T3 (en)	2014-03-10
RU2007112956A (ru)	2008-10-20
AU2005282249A1 (en)	2006-03-16
HK1156637A1 (en)	2012-06-15
RS52265B (sr)	2012-10-31
CN101166754B (zh)	2014-04-23
US20070021324A1 (en)	2007-01-25
EP1799703A4 (en)	2008-09-03
SI2361924T1 (sl)	2014-04-30
HK1140775A1 (en)	2010-10-22
RU2388764C2 (ru)	2010-05-10
DK2177528T3 (da)	2012-03-26
PL1799703T3 (pl)	2010-06-30
PL2177528T3 (pl)	2012-09-28
BRPI0515033A8 (pt)	2019-01-22
KR101317131B1 (ko)	2013-10-10
EP1799703B1 (en)	2010-01-06
ES2451006T3 (es)	2014-03-26
PT2361924E (pt)	2014-03-13
UA91029C2 (uk)	2010-06-25
ATE536363T1 (de)	2011-12-15
RS53248B (sr)	2014-08-29
AU2005282249B2 (en)	2012-08-02
ES2338138T3 (es)	2010-05-04
RS51257B (sr)	2010-12-31
KR20070059137A (ko)	2007-06-11
PT1799703E (pt)	2010-03-04
HRP20120209T1 (hr)	2012-06-30
US7495072B2 (en)	2009-02-24
IL181596A0 (en)	2007-07-04
MX2007002760A (es)	2007-05-18
JP5149008B2 (ja)	2013-02-20
SI1799703T1 (sl)	2010-04-30
DE602005018800D1 (de)	2010-02-25
EP1799703A2 (en)	2007-06-27
IL181596A (en)	2015-10-29
WO2006029393A3 (en)	2007-12-13
PT2177528E (pt)	2012-03-19
EP2177528B1 (en)	2011-12-07
IS8622A (is)	2007-03-16
CN101166754A (zh)	2008-04-23

Publication	Publication Date	Title
PT2361924E (pt)	2014-03-13	Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado
UA93669C2 (ru)	2011-03-10	Способ приготовления полипептидной смеси c использованием гидрогенолиза
FI20050243A7 (fi)	2005-03-07	Stabiilia bakterisidista/läpäisevyyttä parantavaa proteiinifragmenttia koodittava DNA, vektori, isäntäsolu ja menetelmä näiden proteiinipigmenttien valmistamiseksi
WO2009038195A1 (ja)	2009-03-26	変異体ピロリジル－ｔＲＮＡ合成酵素及びこれを用いる非天然アミノ酸組み込みタンパク質の製造方法
MXPA04000597A (es)	2004-04-20	Peptidos novedosos de la proteina g del virus sincicial respiratorio (rsv), y su uso en una vacuna.
WO2004014937A3 (en)	2005-02-17	Thrombin peptide derivatives
GB0001712D0 (en)	2000-03-15	Therapeutic peptides
CY1115096T1 (el)	2016-12-14	Διαδικασια για την παρασκευη μιγματων trifluoroacetyl glatiramer acetate χρησιμοποιωντας καθαρισμενο υδροβρωμικο οξυ
DE60234843D1 (de)	2010-02-04	Modifizierte peptide und deren verwendung zur behandlung von autoimmunkrankheiten
WO2004000870A3 (en)	2004-08-05	Two synthetic peptides for treatment and prevention of cancers
EP1467207A4 (en)	2006-06-07	Screening method
WO2003010196A3 (en)	2004-04-29	Variants and exons of the glyt1 transporter
WO2007026171A8 (en)	2008-04-10	Vdcc gamma-8 ion channel
WO2004013167A3 (en)	2004-05-06	Purified polypeptides from enterococcus faecalis
SG170757A1 (en)	2011-05-30	Polypeptide having esterase activity and recombinant esterase and use thereof
WO2003000718A3 (en)	2003-08-21	Polypeptides comprising t cell epitopes from alpha-fodrin and the uses thereof in treatment of sjögren's syndrome
WO2006059069A3 (en)	2006-08-10	Ion channel